A smooth muscle Cav1.2 calcium channel splice variant underlies hyperpolarized window current and enhanced state-dependent inhibition by nifedipine
- PMID: 17916557
- DOI: 10.1074/jbc.M705478200
A smooth muscle Cav1.2 calcium channel splice variant underlies hyperpolarized window current and enhanced state-dependent inhibition by nifedipine
Abstract
Native smooth muscle L-type Ca(v)1.2 calcium channels have been shown to support a fraction of Ca(2+) currents with a window current that is close to resting potential. The smooth muscle L-type Ca(2+) channels are also more susceptible to inhibition by dihydropyridines (DHPs) than the cardiac channels. It was hypothesized that smooth muscle Ca(v)1.2 channels exhibiting hyperpolarized shift in steady-state inactivation would contribute to larger inhibition by DHP, in addition to structural differences of the channels generated by alternative splicing that modulate DHP sensitivities. In addition, it has also been shown that alternative splicing modulates DHP sensitivities by generating structural differences in the Ca(v)1.2 channels. Here, we report a smooth muscle L-type Ca(v)1.2 calcium channel splice variant, Ca(v)1.2SM (1/8/9(*)/32/Delta33), that when expressed in HEK 293 cells display hyperpolarized shifts for steady-state inactivation and activation potentials when compared with the established Ca(v)1.2b clone (1/8/9(*)/32/33). This variant activates from more negative potentials and generates a window current closer to resting membrane potential. We also identified the predominant cardiac isoform Ca(v)1.2CM clone (1a/8a/Delta9(*)/32/33) that is different from the established Ca(v)1.2a (1a/8a/Delta9(*)/31/33). Importantly, Ca(v)1.2SM channels were shown to be more sensitive to nifedipine blockade than Ca(v)1.2b and cardiac Ca(v)1.2CM channels when currents were recorded in either 5 mM Ba(2+) or 1.8 mM Ca(2+) external solutions. This is the first time that a smooth muscle Ca(v)1.2 splice variant has been identified functionally to possess biophysical property that can be linked to enhanced state-dependent block by DHP.
Similar articles
-
Alternative splicing modulates diltiazem sensitivity of cardiac and vascular smooth muscle Ca(v)1.2 calcium channels.Br J Pharmacol. 2010 Aug;160(7):1631-40. doi: 10.1111/j.1476-5381.2010.00798.x. Br J Pharmacol. 2010. PMID: 20649567 Free PMC article.
-
Smooth muscle-selective alternatively spliced exon generates functional variation in Cav1.2 calcium channels.J Biol Chem. 2004 Nov 26;279(48):50329-35. doi: 10.1074/jbc.M409436200. Epub 2004 Sep 20. J Biol Chem. 2004. PMID: 15381693
-
Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties.Mol Pharmacol. 1998 May;53(5):902-7. Mol Pharmacol. 1998. PMID: 9584217
-
Voltage-dependent calcium channels.Gen Physiol Biophys. 2005 Jun;24 Suppl 1:1-78. Gen Physiol Biophys. 2005. PMID: 16096350 Review.
-
A new L-type calcium channel isoform required for normal patterning of the developing neuromuscular junction.Channels (Austin). 2011 Nov-Dec;5(6):518-24. doi: 10.4161/chan.5.6.17951. Epub 2011 Nov 1. Channels (Austin). 2011. PMID: 21993196 Review.
Cited by
-
CaV1.2/CaV3.x channels mediate divergent vasomotor responses in human cerebral arteries.J Gen Physiol. 2015 May;145(5):405-18. doi: 10.1085/jgp.201511361. J Gen Physiol. 2015. PMID: 25918359 Free PMC article.
-
Understanding alternative splicing of Cav1.2 calcium channels for a new approach towards individualized medicine.J Biomed Res. 2010 May;24(3):181-6. doi: 10.1016/S1674-8301(10)60027-9. J Biomed Res. 2010. PMID: 23554629 Free PMC article.
-
Calfacilitin is a calcium channel modulator essential for initiation of neural plate development.Nat Commun. 2013;4:1837. doi: 10.1038/ncomms2864. Nat Commun. 2013. PMID: 23673622 Free PMC article.
-
1,8-Cineole blocks voltage-gated L-type calcium channels in tracheal smooth muscle.Pflugers Arch. 2018 Dec;470(12):1803-1813. doi: 10.1007/s00424-018-2201-5. Epub 2018 Sep 11. Pflugers Arch. 2018. PMID: 30206706
-
Reviving Cav1.2 as an attractive drug target to treat bladder dysfunction.FASEB J. 2022 Jan;36(1):e22118. doi: 10.1096/fj.202101475R. FASEB J. 2022. PMID: 34939692 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous